Pigmentary retinopathy, macular oedema, and abnormal ERG with mitotane treatment

Ng, Wl.; Toohey, Monty; Mulhall, Lin; Mackey, DA

doi:10.1136/bjo.87.4.500-a

Cited by 8 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mitotane, which is a widely used agent in the treatment of adrenocortical carcinoma, is the only adrenal-specific chemotherapeutic regimen [ 29 , 75 ]. It has been associated with visual blurring, cataracts, visual diplopia, edema, toxic retinopathy with retinal hemorrhage, papilloedema, and retinal pigmentary changes [ 76 ].…”

Section: Reviewmentioning

confidence: 99%

Potential Ophthalmological Side Effects Induced by Anti-Neoplastic Regimens for the Treatment of Genitourinary Cancers: A Review

Sakellakis¹,

Spathas²,

Tsaousis³

et al. 2022

Cureus

View full text Add to dashboard Cite

The outcomes of patients with genitourinary (GU) cancers have been steadily improving in recent years. Novel therapies have entered our armamentarium, while several other regimens are currently being studied in clinical trials. This recent explosion of new agents has improved patient survival and the quality of life for patients, but has also significantly increased the frequency of several side effects. The current review will focus on the potential ocular adverse reactions of GU neoplastic treatments. The broad spectrum of manifestations of ocular toxicity underscores the uniqueness and complexity of the anatomic, physiologic, and metabolic features of the human eye. Most side effects are mild in severity and transient, but some can be severe, disabling, and irreversible. Clinicians should be aware of complications that might be vision threatening and impact the patient's quality of life. In this review, we focused on the ocular toxicity of the antineoplastic regimens that are currently used for the treatment of GU, including prostate cancer, bladder cancer, renal cell carcinoma, testicular cancer, pheochromocytoma, adrenocortical carcinoma, and penile cancer.

show abstract

Section: Reviewmentioning

confidence: 99%